Lung Cancer Clinical Trials

Showing 1361-1380 of 4,288 trials

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009

The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.

Small Cell Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.190 participantsStarted Dec 2024

Westmead, New South Wales, Australia • Wollongong, New South Wales, Australia • Heidelberg, Victoria, Australia +7 more locations

RECRUITINGPhase 3

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

NCT06612151

This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).

Small Cell Lung Cancer

MediLink Therapeutics (Suzhou) Co., Ltd.438 participantsStarted Dec 2024

Guangzhou, Guangdong, China

TERMINATEDPhase 1

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

NCT05241873

This is a Phase 1/2, open-label first-in-human study of the safety, pharmacokinetics (PK), pharmacodynamics, and anti-tumor activity of BLU-451 monotherapy and BLU-451 in combination with platinum-based chemotherapy (carboplatin and pemetrexed). All participants will receive BLU-451 on a 21-day treatment cycle.

Lung Neoplasm MalignantCarcinoma, Non-Small-Cell LungRespiratory Tract Neoplasms+17 more

Blueprint Medicines Corporation103 participantsStarted Mar 2022

Duarte, California, United States • Los Angeles, California, United States • Aurora, Colorado, United States +20 more locations

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Related Searches

Remote Monitoring With Health-Coaching for Lifestyle Changes in Patients With Lung Cancer Related Fatigue

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

Effectiveness of Respiratory Muscle Training with a Mobile Application After Lobectomy

Somesthesia in Cancer Patients: Variability and Influence on Eating Experience

Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC

Liquid Biopsy to Reduce Time to Treatment for Advanced Nonsquamous NSCLC Diagnosed at Outside Sites

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Transcriptional Framework for the Molecular Diagnosis of Response to Immunotherapy in Lung Cancer With Agnostic Potential

An Observational Study to Evaluate the Clinical Utility of the Oncomine Precision Assay Within the Exactis Network

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

Pulmonary Rehabilitation Before Lung Cancer Resection

Avelumab in First-line NSCLC (JAVELIN Lung 100)

Proteomics in Small Cell Lung Cancer

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease